Some health problems are treated by very high dose vitamin D - video and summary
Why Your Doctor's Vitamin D Dose Is Dangerously Wrong?
Cure4Pain: summarized by Claude AI, June 2026
Vitamin D deficiency as a global pandemic
[00:28–03:23] Indian survey data shows alarming rates even in sun-rich regions — Delhi urban adults 76% deficient, pregnant women 96%, elderly 97%; Mumbai adults 70%; southern metros ~88% deficient.
COVID-era data and historical decline
[03:23–04:30] 88% of medical staff were deficient (<40 ng/mL). Historical data show populations maintained D3 levels above 50 ng/mL through the 1990s, then dropped sharply post-2000 due to sunscreen use, sun-avoidance messaging, and indoor lifestyles.
Causes of deficiency
[06:34–09:18] SPF 15+ sunscreen blocks >99% of D synthesis; darker/pigmented skin slows synthesis; post-age 65 synthesis drops ~70%; malabsorption conditions (Crohn's, celiac, bowel bypass), liver/kidney disease, genetic VDR polymorphisms, and magnesium deficiency (a critical cofactor at every step of D3 activation).
The inadequate RDA standard
[10:59–12:21] The 2010 IOM/RDA recommendations (400–800 IU/day, target 20 ng/mL) were designed only to prevent rickets — described as "minimum wage" dosing. For comparison, 45 minutes of sun with 60–70% body exposure produces ~20,000 IU.
Ancestral vs. modern D3 levels
[12:41–14:23] Ancestral primate D3 levels were ~160 ng/mL; pre-modern humans ~120 ng/mL; modern norm is now <40. The presenter argues 60–80 ng/mL is optimal, 40 ng/mL is the minimum for fracture prevention, and ~9,000 IU/day is needed to reach 40 ng/mL via supplementation.
Inverse correlation with disease risk
[15:25–16:53] Higher D3 levels inversely correlate with disease risk — TB, hypertension, heart attacks (<20 ng/mL); osteoporosis, influenza, type 2 diabetes, breast/pancreatic/renal/colon cancer (<60 ng/mL). Cancer risk reduction requires 60–80 ng/mL.
Safety ceilings
[19:31–20:38] No-observed-adverse-effect levels: 10,000 IU/day for adults, 4,000 IU for adolescents (11–17), 2,000 IU for children (1–10). Long-term intake up to 10,000 IU/day is described as safe and physiologically maximizing benefits.
Supplementation protocol by blood level
[24:35–26:16] Maintenance: 10,000 IU/day if <40 ng/mL, 5,000 IU/day if 40–80 ng/mL. Therapeutic dosing by level: <10 ng/mL → 15,000 IU; 10–20 → 12,500 IU; 20–30 → 10,000 IU; 30–40 → 7,500 IU; 40–50 → 5,000 IU. Children: ~200 IU/kg/day. Rough rule: ~1,000 IU per 10 kg body weight.
The "vitamin D hammer" protocol
[27:54–28:28] 60,000 IU daily for 5–7 days, then 60,000 IU weekly (≈8,000–9,000 IU/day equivalent) or 10,000 IU daily for three months, retest, then maintain at 5,000 IU daily or 60,000 IU every 15 days.
Dosing frequency matters
[29:26–30:37] Annual or quarterly dosing is ineffective (D3 half-life is ~48 hours); daily dosing is most effective, weekly is nearly as good. Monthly provides moderate benefit.
Formulations available
[30:43–31:48] Oral powder/granules, oil-based, nanotechnology (most efficient), oral sprays, and intramuscular injectables (600,000 IU loading doses). Quality matters, especially for therapeutic use.
Closing argument
[31:56–33:26] ~90% of unsupplemented populations test at 3–20 ng/mL; correcting deficiency is framed as an obligation, not a favor (quoting Dr. Cicero Coimbra). Conditions linked to deficiency include allergies, asthma, back pain, cancers, cognitive decline, diabetes, hypertension, influenza, MS, obesity, pregnancy risk, rickets, TB, and lupus.
Note on positioning
The presenter advocates dose ranges well above mainstream guidelines. The 60–80 ng/mL target and 10,000 IU/day maintenance align with the Vitamin D Council/Endocrine Society high-end view but exceed IOM/RDA. The "no upper toxicity" claim is stronger than what most published safety reviews state — toxicity is rare at <10,000 IU/day in healthy individuals, but the claim that there is no upper limit is contested and depends heavily on calcium, magnesium, and K2 cofactor status. The 15,000 IU/day therapeutic recommendation for severe deficiency and the Coimbra-protocol framing place this content in the higher-dose advocacy camp rather than consensus guidance.